Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Donna Zemlickis"'
Autor:
Torben Plesner, Philippe Moreau, Ivo Nnane, Andrew Farnsworth, Peter Hellemans, Nibedita Bandyopadhyay, Maria-Victoria Mateos, Albert Oriol, Saad Z. Usmani, Hareth Nahi, Donna Zemlickis, Ajai Chari, Brenda Tromp, Niels W.C.J. van de Donk
Publikováno v:
Nahi, H, Usmani, S Z, Mateos, M-V, van de Donk, N W C J, Moreau, P, Oriol, A, Plesner, T, Bandyopadhyay, N, Hellemans, P, Tromp, B, Nnane, I, Zemlickis, D, Farnsworth, A & Chari, A 2021, ' Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study ', Blood, vol. 138, no. Suppl. 1, 1667 . https://doi.org/10.1182/blood-2021-148990
Introduction: Daratumumab (DARA) is a human monoclonal IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved as monotherapy or in combination with standard-of-care regimens for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fcc75dc285d56f1f5d692605266dfcd
https://portal.findresearcher.sdu.dk/da/publications/802018b7-d210-456f-8fd7-acf3330c9b9a
https://portal.findresearcher.sdu.dk/da/publications/802018b7-d210-456f-8fd7-acf3330c9b9a
Autor:
Matthew G. Krebs, Melissa L. Johnson, Byoung Chul Cho, Se-Hoon Lee, Rachel Kudgus-Lokken, Donna Zemlickis, Anna Mitselos, Eileen Berkay, Joshua M. Bauml, Roland E. Knoblauch, Peter Hellemans, Anna Minchom
Publikováno v:
Cancer Research. 82:CT198-CT198
Background: Amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, is approved for patients with advanced EGFR exon 20 insertion non-small cell lung cancer after progression on platinum-based chemotherapy. First-dose intrave
Autor:
Albert Oriol, Ajai Chari, Niels W.C.J. van de Donk, Man Luo, Donna Zemlickis, Maria-Victoria Mateos, Saad Z. Usmani, Brenda Tromp, Shiyi Yang, Peter Hellemans, Philippe Moreau, Andrew Farnsworth, Torben Plesner, Hareth Nahi
Publikováno v:
Nahi, H, Usmani, S Z, Mateos, M-V, van de Donk, N W C J, Moreau, P, Oriol, A, Plesner, T, Yang, S, Hellemans, P, Tromp, B J, Luo, M, Zemlickis, D, Farnsworth, A & Chari, A 2020, ' Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study ', Journal of Clinical Oncology, vol. 38, no. Suppl. 15, 8537 . https://doi.org/10.1200/JCO.2020.38.15_suppl.8537
Web of Science
Web of Science
8537 Background: Intravenous DARA (DARA IV) is approved for the treatment of MM. In Part 2 of PAVO, DARA SC, a concentrated, pre-mixed SC co-formulation of DARA and recombinant human hyaluronidase PH20 (rHuPH20), was well tolerated, with a low infusi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba2fb680a0d361757e6574cc41a43a2c
https://portal.findresearcher.sdu.dk/da/publications/1d4e897d-77b0-4076-89fb-3d41603a0d3a
https://portal.findresearcher.sdu.dk/da/publications/1d4e897d-77b0-4076-89fb-3d41603a0d3a
Autor:
Roland Elmar Knoblauch, Keunchil Park, Melissa Lynne Johnson, Nahor Haddish-Berhane, Donna Zemlickis, Anna Minchom, Matthew G Krebs, Peter Hellemans, Anna Mitselos, Byoung Chul Cho, Francis Meacle
Publikováno v:
Journal of Clinical Oncology. 39:TPS3150-TPS3150
TPS3150 Background: Amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody with immune cell-directing activity, targets activating/resistance EGFR mutations and MET mutations/amplifications. Amivantamab has demonstrated antit